Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,226 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial.
Tardif JC, Grégoire J, L'Allier PL, Ibrahim R, Lespérance J, Heinonen TM, Kouz S, Berry C, Basser R, Lavoie MA, Guertin MC, Rodés-Cabau J; Effect of rHDL on Atherosclerosis-Safety and Efficacy (ERASE) Investigators. Tardif JC, et al. Among authors: ibrahim r. JAMA. 2007 Apr 18;297(15):1675-82. doi: 10.1001/jama.297.15.jpc70004. Epub 2007 Mar 26. JAMA. 2007. PMID: 17387133 Clinical Trial.
Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions.
Tardif JC, Grégoire J, L'Allier PL, Anderson TJ, Bertrand O, Reeves F, Title LM, Alfonso F, Schampaert E, Hassan A, McLain R, Pressler ML, Ibrahim R, Lespérance J, Blue J, Heinonen T, Rodés-Cabau J; Avasimibe and Progression of Lesions on UltraSound (A-PLUS) Investigators. Tardif JC, et al. Among authors: ibrahim r. Circulation. 2004 Nov 23;110(21):3372-7. doi: 10.1161/01.CIR.0000147777.12010.EF. Epub 2004 Nov 8. Circulation. 2004. PMID: 15533865 Clinical Trial.
The drug-based pipeline against restenosis.
Keller PF, Ibrahim R, Tardif JC. Keller PF, et al. Among authors: ibrahim r. Expert Opin Emerg Drugs. 2005 Feb;10(1):67-86. doi: 10.1517/14728214.10.1.67. Expert Opin Emerg Drugs. 2005. PMID: 15757404 Review.
Effects of the antioxidant succinobucol (AGI-1067) on human atherosclerosis in a randomized clinical trial.
Tardif JC, Grégoire J, L'Allier PL, Ibrahim R, Anderson TJ, Reeves F, Title LM, Schampaert E, LeMay M, Lespérance J, Scott R, Guertin MC, Brennan ML, Hazen SL, Bertrand OF; CART-2 Investigators. Tardif JC, et al. Among authors: ibrahim r. Atherosclerosis. 2008 Mar;197(1):480-6. doi: 10.1016/j.atherosclerosis.2006.11.039. Epub 2007 Jan 9. Atherosclerosis. 2008. PMID: 17214993 Clinical Trial.
Clopidogrel 600-mg double loading dose achieves stronger platelet inhibition than conventional regimens: results from the PREPAIR randomized study.
L'Allier PL, Ducrocq G, Pranno N, Noble S, Ibrahim R, Grégoire JC, Azzari F, Nozza A, Berry C, Doucet S, Labarthe B, Théroux P, Tardif JC; PREPAIR Study Investigators. L'Allier PL, et al. Among authors: ibrahim r. J Am Coll Cardiol. 2008 Mar 18;51(11):1066-72. doi: 10.1016/j.jacc.2007.12.013. J Am Coll Cardiol. 2008. PMID: 18342223 Free article. Clinical Trial.
Efficacy and safety of pyridoxal 5'-phosphate (MC-1) in high-risk patients undergoing coronary artery bypass graft surgery: the MEND-CABG II randomized clinical trial.
MEND-CABG II Investigators; Alexander JH, Emery RW Jr, Carrier M, Ellis SJ, Mehta RH, Hasselblad V, Menasche P, Khalil A, Cote R, Bennett-Guerrero E, Mack MJ, Schuler G, Harrington RA, Tardif JC. MEND-CABG II Investigators, et al. JAMA. 2008 Apr 16;299(15):1777-87. doi: 10.1001/jama.299.15.joc80027. Epub 2008 Apr 1. JAMA. 2008. PMID: 18381567 Clinical Trial.
1,226 results